Advances in the Treatment of Genitourinary Cancers

Saturday, May 10, 2014
8:00 am – 12:30 pm
Joseph B. Martin Conference Center at Harvard Medical School
77 Avenue Louis Pasteur
Boston, MA

Offered by Dana-Farber/Brigham and Women’s Cancer Center and Harvard Medical School Department of Continuing Education.

Register Online Now

Agenda  |  Faculty Speakers  |  Credits  |  Registration  |  Directions

 

Course Overview

This half-day program, designed for medical and radiation oncologists, urologists, surgeons, primary care physicians, and other interested providers, will examine best practices for multidisciplinary management of genitourinary cancers. Through case presentations and discussion, specialists will review treatment options for prostate, bladder, and kidney cancer, and metastatic germ cell tumors.

Specific topics for discussion will include: PSA screening, immunotherapy in kidney cancer, high-risk prostate cancer, management of non-muscle invasive bladder cancer, and post-chemotherapy surgery for metastatic germ cell tumors.

Learning Objectives

At the conclusion of this course, attendees will be able to:

- Determine the most effective treatment options for patients with high-risk prostate cancer,
- Describe which treatments for castration-resistant prostate cancer are appropriate at which part of the cancer spectrum,
- Summarize emerging immunotherapies for metastatic renal cell carcinoma, and
- Discuss when surgery is appropriate after chemotherapy for metastatic germ cell tumors (GCT)

ACGME Competencies: This course is designed to enhance one or more of the following Accreditation Council of Graduate Education competencies: Patient care, Medical knowledge, Interpersonal and communication skills.

About the Genitourinary Oncology Program at
Dana-Farber/Brigham and Women’s Cancer Center

The Genitourinary Oncology Program is a multidisciplinary and multispecialty care and treatment center for patients with all genitourinary malignancies, including cancers of the prostate, testes, bladder and kidney. Through this program, referring physicians and their patients have access to tailored treatment plans based on the latest surgical, chemotherapy, and radiation treatment approaches, including access to NCI clinical trials.

Research is an integral part of our work in the Genitourinary Oncology Program. Physicians and researchers are engaged in studies involving prevention and early-detection strategies, assessment of new therapies, quality-of-life studies, and the analysis of tissue and blood samples to better understand the biology of the malignancies and relation to patient outcomes. This research enables us to provide more effective diagnostics and safer and more effective treatments to patients.


Agenda

8:00 am
Registration Check-in and Continental Breakfast

8:25 am
Welcome
Philip W. Kantoff, MD
Christopher J. Sweeney, MBBS

8:30 am
PSA Screening: Do the Risks Outweigh the Benefits?
Mark Pomerantz, MD

8:45 am
Q&A

8:50 am
How to Sequence all the New Castration-Resistant Prostate Cancer (CRPC) Therapies
Philip W. Kantoff, MD

9:05 am
Q&A

9:10 am
High-Risk Prostate Cancer: Radiation and Hormonal Therapy Options and Current Clinical Trials
Anthony V. D’Amico, MD, PhD

9:25 am
Q&A

9:30 am
Management of Side Effects of Radical Prostatectomy
Quoc-Dien Trinh, MD

9:45 am
Q&A

9:50 am
Which Patients with High-Risk Prostate Cancer are Suitable for Surgery?
Adam S. Kibel, MD

10:05 am
Q&A with Panel Discussion

10:30 am
Break

10:50 am
Management of Non-Muscle Invasive Bladder Cancer
Jerome Richie, MD

11:05 am
Q&A

11:10 am
Update in Cystectomy and Nephrouretectomy Options
Steven Chang, MD

11:25 am
Q&A

11:30 am
The Return of Immunotherapy in Renal Cell Carcinoma
Toni Choueiri, MD

11:45 am
Q&A

11:50 am
Post-Chemotherapy Surgery for Metastatic Germ Cell Tumors: When and Whom?
Christopher J. Sweeney, MBBS

12:05 pm
Q&A

12:10 pm – 12:30 pm
Closing Remarks
Philip W. Kantoff, MD
Christopher J. Sweeney, MBBS

 Please note: program changes/substitutions may be made without notice.


Faculty Speakers

Philip W. Kantoff, MD
Course Co-Director
Chief, Division of Solid Tumor Oncology,
Director, Lank Center for Genitourinary Oncology,
Dana-Farber/Brigham and Women’s Cancer Center;
Professor of Medicine,
Harvard Medical School

Christopher J. Sweeney, MBBS
Course Co-Director
Medical Oncologist, Genitourinary Oncology,
Dana-Farber/Brigham and Women’s Cancer Center;
Associate Professor of Medicine,
Harvard Medical School

Steven Chang, MD, MS
Surgical Oncologist, Genitourinary Oncology,
Dana-Farber/Brigham and Women’s Cancer Center;
Instructor in Surgery,
Harvard Medical School

Toni Choueiri, MD
Director, Kidney Cancer Center,
Clinical Director, Lank Center for Genitourinary Cancer,
Dana-Farber/Brigham and Women’s Cancer Center;
Associate Professor of Medicine,
Harvard Medical School

Anthony V. D’Amico, MD, PhD
Chief, Division of Genitourinary Radiation Oncology,
Dana-Farber/Brigham and Women’s Cancer Center;
Professor of Radiation Oncology,
Harvard Medical School

Adam S. Kibel, MD
Surgical Director, Lank Center for Genitourinary Oncology,
Dana-Farber/Brigham and Women’s Cancer Center;
Chief, Urologic Surgery,
Brigham and Women’s Hospital;
Professor of Surgery,
Harvard Medical School

Mark Pomerantz, MD
Medical Oncologist, Genitourinary Oncology,
Dana-Farber/Brigham and Women’s Cancer Center;
Assistant Professor of Medicine,
Harvard Medical School

Jerome Richie, MD
Surgical Oncologist, Genitourinary Oncology,
Dana-Farber/Brigham and Women’s Cancer Center;
Elliott Carr Cutler Professor of Surgery,
Harvard Medical School

Quoc-Dien Trinh, MD
Surgical Oncologist, Genitourinary Oncology,
Dana-Farber/Brigham and Women’s Cancer Center;
Assistant Professor of Surgery,
Harvard Medical School

Harvard Medical School (HMS) adheres to all ACCME Essential Areas, Standards, and Policies. It is HMS’s policy that those who have influenced the content of a CME activity (e.g. planners, faculty, authors, reviewers and others) disclose all relevant financial relationships with commercial entities so that HMS may identify and resolve any conflicts of interest prior to the activity. These disclosures will be provided in the activity materials along with disclosure of any commercial support received for the activity. Additionally, faculty members have been instructed to disclose any limitations of data and unlabeled or investigational uses of products during their presentations.

 

Accreditation

The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Harvard Medical School designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Registration Information


Registration fees
:

$50.00 through May 5, 2014
$60.00 after May 5, 2014

Registration fees include course materials, continental breakfast, and complimentary parking.

Register Online Now

To register by mail, send completed GU CME registration form and check made payable to DF/BWCC by April 28, 2014 to:

Genitourinary Cancers CME 2014
Dana-Farber/Brigham and Women’s Cancer Center
Attn: Kamira Wooten
450 Brookline Avenue, OS381
Boston, MA 02215

If you have food allergies, or if you require accommodations such as an ASL interpreter, materials in alternative format or wheelchair access, please email kwooten@partners.org or call (800) 553-3787.

Directions and Parking

This conference will take place at the Joseph B. Martin Conference Center at Harvard Medical School, located at 77 Avenue Louis Pasteur in Boston, MA.  Complimentary parking is available on-site in the Conference Center’s garage. For directions, visit: http://www.theconfcenter.hms.harvard.edu/directions/

 

Take The First Step
Make AN Appointment

Boston, Main Campus
877-332-4294

Online Appointments

South Shore
781-624-5000


MILFORD
877-332-4294

Patient Stories

Read inspiring stories of strength,
hope and perseverance.

© 2014; Dana-Farber/Brigham and Women's Cancer Center, Boston, MA